Yıl: 2023 Cilt: 32 Sayı: 2 Sayfa Aralığı: 94 - 102 Metin Dili: İngilizce DOI: 10.4274/mirt.galenos.2022.97658 İndeks Tarihi: 11-07-2023

Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study

Öz:
Objectives: This prospective study was planned to compare the predictive value of dynamic 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in locally advanced breast cancer patients (LABC) receiving neoadjuvant chemotherapy (NAC). Methods: Twenty seven patients with LABC [median age: 47, (26-66)] underwent a dynamic18F-FDG PET study at baseline, and after 2-3 cycles of (NAC) were included (interim). Maximum standardized uptake value (SUVmax) values and SUV ratios for the 2 nd, 5th, 10th, and 30th minutes and dynamic curve slope (SL) values and SL ratios were measured using18F-FDG dynamic data. In addition, the values of SUVmean (2minSUVmean), SULpeak (2minSULpeak), metabolic volume (2minVol), and total lesion glycolysis (2minTLG) were measured for the first 2 min. Percent changes between baseline and interim studies were calculated and compared with the pathological results as the pathological complete response (PCR) or the pathological non-complete response (non-PCR). Receiver operating characteristic curves were obtained to calculate the area under the curve to predict PCR. Optimal threshold values were calculated to discriminate between PCR and non-PCR groups. Results: Baseline study SUV 30 (p=0.044), SUV 30/2 (p=0.041), SUV 30/5 (p=0.049), SUV 30/10 (p=0.021), SL 30/2 (p=0.029) and SL 30/5 (p=0.027) values were statistically significant different between PCR and non-PCR groups. The percentage changes of 2minVol between PCR and non-PCR groups were statistically significant. For the threshold value of -67.6% change in 2minVol, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 87.2%, 77.8%, 63.6%, 93.3%, and 80.7%, respectively (area under the curve: 0.826, p=0.009). Conclusion: Semiquantitative parameters for dynamic 18F-FDG PET can predict PCR. % changes in 2minVol can identify non-responding patients better than other parameters.
Anahtar Kelime:

Lokal İleri Evre Meme Kanserli Hastalarda Neoadjuvan Kemoterapi Yanıtı Öngörüsünde Dinamik 18F-FDG PET/BT’nin Değeri: Prospektif Çalışma

Öz:
Amaç: Bu prospektif çalışmada neoadjuvan kemoterapi (NAC) alan lokal ileri meme kanseri hastalarda (LABC) dinamik18F-florodeoksiglukoz (FDG) pozitron emisyon tomografisi/bilgisayarlı tomografinin (PET/BT), NAC yanıt öngörüsünü araştırdık. Yöntem: LABC’li 27 hastaya [medyan yaş: 47, (26-66)] NAC öncesi ve 2-3 kür kemoterapi sonrası dinamik18F-FDG PET çalışması uyguladık. Dinamik çalışmanın 2., 5., 10 ve 30. dakikalarında maksimum standartlaştırılmış alım değeri (SUVmaks) değerleri, SUV oranları ile dinamik eğri eğim (SL) değerleri ve SL oranları, 18F-FDG dinamik verileri kullanılarak ölçüldü. Ayrıca ilk 2 dakika için SUVmean (2minSUVmean), SULpeak (2minSULpeak), metabolik volume (2minVol), and total lezyon glikoliz (2minTLG) değerlerini hesapladık. Parametrelerin tedavi öncesi ve interim çalışma arasındaki yüzde değişimlerini hesapladık ve patolojik sonuçlar [patolojik tam yanıt (PCR) olan ve olmayan (non-PCR)] ile karşılaştırdık. Parametrelerin patolojik yanıtı (PCR ve non-PCR) ayırt edebilmesi için ROC eğrisi kullanarak en uygun eşik değerleri hesapladık. Bulgular: Tedavi öncesi SUV 30 (p=0,044), SUV 30/2 (p=0,041), SUV 30/5 (p=0,049), SUV 30/10 (p=0,021), SL 30/2 (p=0,029) ve SL 30/5 (p=0,027) değerleri PCR ve non-PCR hasta grupları arasında istatistiksel anlamlı farklı idi. Yüzde (%) değişim 2minVol, PCR ve non-PCR hasta grupları arasında istatistiksel olarak anlamlı farklılık vardı. 2minVol’deki -%67,6 değişim eşik değeri için duyarlılık %87,2, özgüllük %77,8, pozitif öngörü değeri %63,6, negatif öngörü değeri %93,3 ve doğruluk %80,7 idi (eğrinin altındaki alan: 0,826, p=0,009). Sonuç: Dinamik 18F-FDG PET parametreleri patolojik yanıtı öngörebilir. 2minVol’deki % değişiklikler, non-PCR hastaları diğer parametrelerden daha iyi belirleyebilir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000;18:1558-1569.
  • 2. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-785.
  • 3. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469.
  • 4. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
  • 5. Tian F, Shen G, Deng Y, Diao W, Jia Z. The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review. Eur Radiol 2017;27:4786-4796.
  • 6. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, Lehner B, Haberkorn U, Stroebel P, Kasper B. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 2010;51:551-558.
  • 7. Strauss LG, Pan L, Cheng C, Haberkorn U, Dimitrakopoulou-Strauss A. Shortened acquisition protocols for the quantitative assessment of the 2-tissue-compartment model using dynamic PET/CT 18F-FDG studies. J Nucl Med 2011;52:379-385.
  • 8. unnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res 2011;17:2400-2409.
  • 9. Payan N, Presles B, Brunotte F, Coutant C, Desmoulins I, Vrigneaud JM, Cochet A. Biological correlates of tumor perfusion and its heterogeneity in newly diagnosed breast cancer using dynamic first-pass 18F-FDG PET/ CT. Eur J Nucl Med Mol Imaging 2020;47:1103-1115.
  • 10. Kajáry K, Lengyel Z, Tőkés AM, Kulka J, Dank M, Tőkés T. Dynamic FDG- PET/CT in the initial staging of primary breast cancer: clinicopathological correlations. Pathol Oncol Res 2020;26:997-1006.
  • 11. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
  • 12. Strauss LG, Koczan D, Klippel S, Pan L, Willis S, Sachpekidis C, Dimitrakopoulou-Strauss A. Dynamic PET with (18)F-Deoxyglucose (FDG) and quantitative assessment with a two-tissue compartment model reflect the activity of glucose transporters and hexokinases in patients with colorectal tumors. Am J Nucl Med Mol Imaging 2013;3:417-424.
  • 13. Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison KH, Schubert EK, Mankoff DA. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res 2010;16:2803-2810.
  • 14. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008;26:4449-4457.
  • 15. Partridge SC, Vanantwerp RK, Doot RK, Chai X, Kurland BF, Eby PR, Specht JM, Dunnwald LK, Schubert EK, Lehman CD, Mankoff DA. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. J Magn Reson Imaging 2010;32:1124- 1131.
  • 16. Rusten E, Rødal J, Revheim ME, Skretting A, Bruland OS, Malinen E. Quantitative dynamic 18FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta Oncol 2013;52:1160-1167.
  • 17. Tuncel M, Kupik O, Kiratli P, Erbas B. Practical measures of dynamic 18 FDG time-activiy curves. Eur J Nucl Med Mol Imaging. 2015(Suppl 1):375.
  • 18. Dimitrakopoulou-Strauss A, Pan L, Strauss LG. Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients. Cancer Imaging 2012;12:283-289.
APA kupik o, Tuncel M, Özgen Kıratlı P, Gülsün Akpınar M, Altundag K, Basaran Demirkazik F, Erbas B (2023). Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. , 94 - 102. 10.4274/mirt.galenos.2022.97658
Chicago kupik osman,Tuncel Murat,Özgen Kıratlı Pınar,Gülsün Akpınar Meltem,Altundag Kadri,Basaran Demirkazik Figen,Erbas Belkıs Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. (2023): 94 - 102. 10.4274/mirt.galenos.2022.97658
MLA kupik osman,Tuncel Murat,Özgen Kıratlı Pınar,Gülsün Akpınar Meltem,Altundag Kadri,Basaran Demirkazik Figen,Erbas Belkıs Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. , 2023, ss.94 - 102. 10.4274/mirt.galenos.2022.97658
AMA kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Basaran Demirkazik F,Erbas B Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. . 2023; 94 - 102. 10.4274/mirt.galenos.2022.97658
Vancouver kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Basaran Demirkazik F,Erbas B Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. . 2023; 94 - 102. 10.4274/mirt.galenos.2022.97658
IEEE kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Basaran Demirkazik F,Erbas B "Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study." , ss.94 - 102, 2023. 10.4274/mirt.galenos.2022.97658
ISNAD kupik, osman vd. "Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study". (2023), 94-102. https://doi.org/10.4274/mirt.galenos.2022.97658
APA kupik o, Tuncel M, Özgen Kıratlı P, Gülsün Akpınar M, Altundag K, Basaran Demirkazik F, Erbas B (2023). Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. Molecular Imaging and Radionuclide Therapy, 32(2), 94 - 102. 10.4274/mirt.galenos.2022.97658
Chicago kupik osman,Tuncel Murat,Özgen Kıratlı Pınar,Gülsün Akpınar Meltem,Altundag Kadri,Basaran Demirkazik Figen,Erbas Belkıs Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. Molecular Imaging and Radionuclide Therapy 32, no.2 (2023): 94 - 102. 10.4274/mirt.galenos.2022.97658
MLA kupik osman,Tuncel Murat,Özgen Kıratlı Pınar,Gülsün Akpınar Meltem,Altundag Kadri,Basaran Demirkazik Figen,Erbas Belkıs Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. Molecular Imaging and Radionuclide Therapy, vol.32, no.2, 2023, ss.94 - 102. 10.4274/mirt.galenos.2022.97658
AMA kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Basaran Demirkazik F,Erbas B Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. Molecular Imaging and Radionuclide Therapy. 2023; 32(2): 94 - 102. 10.4274/mirt.galenos.2022.97658
Vancouver kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Basaran Demirkazik F,Erbas B Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study. Molecular Imaging and Radionuclide Therapy. 2023; 32(2): 94 - 102. 10.4274/mirt.galenos.2022.97658
IEEE kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Basaran Demirkazik F,Erbas B "Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study." Molecular Imaging and Radionuclide Therapy, 32, ss.94 - 102, 2023. 10.4274/mirt.galenos.2022.97658
ISNAD kupik, osman vd. "Value of Dynamic 18F-FDG PET/CT in Predicting the Success of Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer: A Prospective Study". Molecular Imaging and Radionuclide Therapy 32/2 (2023), 94-102. https://doi.org/10.4274/mirt.galenos.2022.97658